Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Lung Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Non Small Cell Lung Cancer (3692)

Lung Non-Squamous Non-Small Cell Cancer (164)

Lung Non-Small Cell Squamous Cancer (111)

Non Small Cell Lung Cancer (3692)

Lung Non-Squamous Non-Small Cell Cancer (164)

Lung Non-Small Cell Squamous Cancer (111)

›

No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
PD-L1 underexpression	Lung Adenocarcinoma	PD-L1 underexpression	Lung Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	durvalumab + tremelimumab-actl Sensitive: A2 - Guideline durvalumab + tremelimumab-actl Sensitive : A2	durvalumab + tremelimumab-actl Sensitive: A2 - Guideline durvalumab + tremelimumab-actl Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B